Rohto Pharmaceutical
VC Fund
Osaka, Japan
Rohto Pharmaceutical is a manufactures and markets pharmaceuticals and cosmetics products. The Company's products include eyewash, bath soaps, gastrointestinal medicine, and hand cream. Rohto Pharmaceutical also has a license agreement with its subsidiary, Mentholatum (US) to sell their brand products. The Company also manufactures contactlenses and health foods.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Rohto Pharmaceutical invests in
Stages Rohto Pharmaceutical invests in
Countries Rohto Pharmaceutical invests in
Round sizes
Round size
- Series A
- $4M–$10M
- Corporate Round
- $6M–$17M
Investment Focus
Industry
- Health Care 8 (47%)
- Biotechnology 4 (24%)
- Manufacturing 4 (24%)
- Medical 3 (18%)
- Artificial Intelligence 3 (18%)
Stage
- Corporate Round 4 (24%)
- Seed 3 (18%)
- Series A 3 (18%)
- Series B 3 (18%)
- Series C 2 (12%)
Country
- Japan 10 (59%)
- Israel 1 (6%)
- Taiwan 1 (6%)
- Australia 1 (6%)
- South Korea 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Australis Scientific
|
Australis Scientific is a healthcare technology company that develops novel neuromodulation devices to treat lower urinary tract symptoms, including overactive bladder and urinary incontinence. The company designs wearable, non-invasive systems that deliver peripheral nerve stimulation through patch-based devices intended to support bladderfunction management. Its core development work focuses on transcutaneous tibial nerve stimulation technology integrated into compact, user-friendly medical wearables. Australis Scientific also engages in clinical development, device prototyping, and human factors engineering to refine usability and therapeutic performance. The company collaborates with research and healthcare partners to evaluate device effectiveness and support regulatory and clinical validation processes. In addition, Australis Scientific works on product commercialization efforts aimed at bringing neuromodulation-based therapies into broader clinical use for urological care. | $6M / Corporate Round / Nov 24, 2025 | |
|
Fast Beauty
|
Fast Beauty is a manufacturing company that manufactures beauty products such as hair products, cosmetics, and hair colour. | $11M / Series B / Nov 13, 2025 | |
Human Life CORD
|
HLC is a Japan-originated cell therapy company building a first-in-class global ecosystem for UC-MSC–based products. By transforming umbilical cord tissue into a scalable medical resource, we enable reliable, high-quality cell therapy manufacturing at global scale. | $12.7M / Series C / Oct 09, 2025 | |
EXORPHIA
|
EXORPHIA is a biotechnology startup focused on creating innovative medicines through the use of extracellular vesicles. The company is involved in the research, development, production, and marketing of exosome-based drugs derived from human cells. EXORPHIA operates in two primary sectors: the Drug Discovery Business, which seeks to commercializeexosomes for pharmaceutical applications, and the Non-Drug Discovery Business, which markets exosomes as raw materials for non-medical products. | Corporate Round / Aug 20, 2025 | |
Baibys
|
Baibys is a medical automated platform that provides AI and robotics-based autonomous sperm selection solutions for IVF. | $4.5M / Series A / Aug 08, 2024 | |
Zeroco
|
Zeroco is a logistics company that provides large-scale food storage and technology based logistics services. | $4M / Series A / Jul 23, 2024 | |
Recursive
|
Recursive is a technology firm that develops software solutions to enhance business processes using AI and physics simulations. | Seed / Jun 24, 2024 | |
S-Alpha Therapeutics
|
S-Alpha Therapeutics is a digital health company developing software-based therapeutic solutions by combining biotechnology and IT. It focuses on digital therapeutics for conditions such as pediatric myopia and other unmet medical needs. The company builds clinically validated SaMD products, collaborates with global partners, and advances AI-drivenhealthcare solutions to transform treatment approaches. | $16.7M / Corporate Round / Mar 29, 2024 | |
InnoJin
|
InnoJin is a healthcare technology firm that provides consulting, collecting, analyzing, and giving information on medical services. | $3.3M / Series B / Mar 01, 2024 | |
Plantx
|
Plantx is a Services specializing in artificial light plant factories, integrated environmental control system (SAIBAIX) services, consulting services for improving existing factories, and support services for establishing new factories. | $15.9M / Series E / Nov 30, 2023 | |
| See all 17 investments → | |||
Co-Investors
Dai-ichi Life
4 deals together
Alfresa Holdings
1 deal together
All Nippon Airways Trading
1 deal together
ANA Holdings
1 deal together
ArTra
1 deal together
Chubu Electric Power
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Rohto Pharmaceutical invest in?
Rohto Pharmaceutical invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Corporate Round and Seed stage. Most of the 17 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Rohto Pharmaceutical's check size?
Rohto Pharmaceutical typically joins rounds of $4M–$10M at Series A and $6M–$17M at Corporate Round. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Rohto Pharmaceutical participates in.
When did Rohto Pharmaceutical last invest?
The most recent investment recorded for Rohto Pharmaceutical closed in Nov 2025. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
